The FDA granted fast track designation to PAS-004, a macrocyclic MEK inhibitor, for NF1-associated plexiform neurofibromas ...
Explore the latest statistics on cutaneous melanoma: why incidence rates are rising by 1.2% annually while mortality is ...
Bruce Springsteen's three-hour show, which kicked off in Minnesota, goes to the head of the class in balancing rock ...
The Company is currently conducting a Phase 1/1b multicenter, open-label, dose escalation trial of PAS-004 in adult participants with symptomatic, inoperable, incompletely resected, or recurrent ...
Both photodynamic therapy (PDT) and immunotherapy are two of the biggest areas of cancer therapy with the potential to ...
I obsessively avoided trailers and ignored announcements about new cast members — a deliberate choice to let the surprises ...
The title doesn’t refer to a void into which detectives disappear, but to Harry Hole, the fictional Norwegian sleuth created ...
FDA review uncertainty, failed phase 3 for ersodetug in HI, high-risk upLIFT trial, tight cash runway—read more macro ...
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of ...
The actor makes a commanding and vituperative star turn in Mark Rosenblatt’s play on Broadway about the children’s author, ...
Endoscopic ultrasound-guided gastrojejunostomy offers the best clinical success among all other techniques used for palliation of malignant gastric outlet obstruction.
Title: Results from a Pilot Study of HyBryte (TM) (topical synthetic hypericin) versus Valchlor (R) (mechlorethamine) in the Treatment of CTCL attended by Dr. Christopher Pullion, Medical Director, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results